Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 59

HOS-112201 · Präparat HOS-093615

The increase in progestin exposure may lead to related side effects (e.g., insulin resistance, dyslipidemia, acne and spotting), thus possibly affecting the compliance. LIPID-MODIFYING AGENTS HMG-CoA reductase inhibitors Simvastatin Simvastatin and lovastatin are highly Co-administration of Lovastatin dependent on CYP3A4 for their simvastatin or lovastatin with metabolism and co-administration with REYATAZ is contraindicated REYATAZ may result in increased due to an increased risk of concentrations. myopathy including rhabdomyolysis (see section 4.3). Atorvastatin The risk of myopathy including Co-administration of rhabdomyolysis may also be increased with atorvastatin with REYATAZ is atorvastatin, which is also metabolised by not recommended. If the use of CYP3A4. atorvastatin is considered strictly necessary, the lowest possible dose of atorvastatin should be administered with careful safety monitoring (see section 4.4). Pravastatin Although not studied, there is a potential Caution should be exercised. Fluvastatin for an increase in pravastatin or fluvastatin exposure when co-administered with protease inhibitors. Pravastatin is not metabolised by CYP3A4. Fluvastatin is partially metabolised by CYP2C9. Other lipid-modifying agents Lomitapide Lomitapide is highly dependent on Co-administration of CYP3A4 for metabolism and co- lomitapide and REYATAZ administration with REYATAZ with with ritonavir is ritonavir may result in increased contraindicated due to a concentrations. potential risk of markedly increased transaminase levels and hepatotoxicity (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) fluvastatin (HOS-086305) lead (HOS-085592) ritonavir (HOS-084521) pravastatin (HOS-086306)